Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α

被引：0
|
作者：
de Souza, P. L.
Radulovic, S.
Beck, J.
Pendergrass, K.
Siddique, N.
Dutcher, J. P.
Berkenblit, A.
Thiele, A.
Krygowski, M.
Hudes, G. R.
机构：
[1] St George Hosp, Ctr Canc, Kogarah, NSW, Australia
[2] Univ Klini Mainz, Mainz, Germany
[3] Kansas City Canc Ctr, Kansas City, MO USA
[4] Sharp Hlth Care, San Diego, CA USA
[5] Our Lady Mercy Med Ctr, Bronx, NY USA
[6] Wyeth Pharmaceut, Cambridge, MA USA
[7] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5116
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Is temsirolimus more safe and effective than interferon α for the treatment of advanced renal cell carcinoma?
    Ali-Reza Golshayan
    Ronald M Bukowski
    Nature Clinical Practice Urology, 2007, 4 : 586 - 587
  • [22] Is temsirolimus more safe and effective than interferon a for the treatment of advanced renal cell carcinoma?
    Golshayan, Ali-Reza
    Bukowski, Ronald M.
    NATURE CLINICAL PRACTICE UROLOGY, 2007, 4 (11): : 586 - 587
  • [23] Patients with metastatic renal cell carcinoma treated with everolimus in REACT: Hyperglycemia and hypercholesterolemia and associated outcomes.
    Bono, Petri
    Gogov, Svetozar
    Panneerselvam, Ashok
    Garay, Carlos A.
    Gruenwald, Viktor
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma
    Malizzia, Lois J.
    Hsu, Arlene
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (04) : 639 - 646
  • [25] Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
    Arthur S. Zbrozek
    Gary Hudes
    Donna Levy
    Andrew Strahs
    Anna Berkenblit
    Robert De Marinis
    Shreekant Parasuraman
    PharmacoEconomics, 2010, 28 : 577 - 584
  • [26] Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma
    Zbrozek, Arthur S.
    Hudes, Gary
    Levy, Donna
    Strahs, Andrew
    Berkenblit, Anna
    DeMarinis, Robert
    Parasuraman, Shreekant
    PHARMACOECONOMICS, 2010, 28 (07) : 577 - 584
  • [27] Profile of temsirolimus in the treatment of advanced renal cell carcinoma
    Staehler, Michael
    Haseke, Nicolas
    Khoder, Wael
    Stief, Christian G.
    ONCOTARGETS AND THERAPY, 2010, 3 : 191 - 196
  • [28] Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    Motzer, Robert J.
    Hudes, Gary R.
    Curti, Brendan D.
    McDermott, David F.
    Escudier, Bernard J.
    Negrier, Sylvie
    Duclos, Brigitte
    Moore, Laurence
    O'Toole, Timothy
    Boni, Joseph P.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3958 - 3964
  • [29] Temsirolimus in the treatment of advanced renal-cell carcinoma
    Zolnierek, Jakub
    ONCOLOGY IN CLINICAL PRACTICE, 2009, 5 : C12 - C20
  • [30] Temsirolimus for advanced renal-cell carcinoma - Reply
    Hudes, Gary
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (10): : 1050 - 1051
12345